BOULDER, Colo., Jan. 30, 2015 /PRNewswire/ -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2015 third quarter ended December 31, 2014.
The Company posted quarterly net revenue of $2.608 million for a quarterly net loss of $417 thousand, or $(0.04) per share. These results compare to net revenue of $2.716 million for net income of $33 thousand, or $0.00 per share, in the year-ago quarter. Gross margin on net revenue was 46.6 percent in the fiscal 2015 third quarter and 52.4 percent in the fiscal 2014 third quarter. Gross margin on net revenue was lower in the fiscal 2015 third quarter as a result of higher material costs, scrap costs, higher reserve for obsolescence, and mix of product sold. The medical device excise tax is included in other expense.
The Company posted nine months net revenue of $7.364 million for a nine months net loss of $1.034 million, or $(0.10) per share. These results compare to net revenue of $8.043 million for a net loss of $329 thousand, or $(0.04) per share, in the year-ago nine months. Gross margin on net revenue was 47.8 percent in the fiscal 2015 nine months and 53.3 percent in the fiscal 2014 nine months. Gross margin on net revenue was lower in the fiscal 2015 nine months as a result of higher material costs, scrap costs, higher reserve for obsolescence, and higher unit overhead costs on lower sales volume. The medical device excise tax is included in other expense.
"Although our revenue for the third quarter decreased four percent compared to last year's third quarter, we were pleased with our 14 percent sequential growth from this year's second quarter," said Greg Trudel, President and CEO. "During the third quarter we launched our new AEM EndoShield™ Burn Protection System and are happy to see its enthusiastic reception by the market. Since our first quarter of this fiscal year we have increased our channel presence and expect additional revenue to be gained from that focus and increase. Encision is executing to our plan of increasing market awareness of the devastating clinical and economic risk potential of stray energy and of driving customer demand through education and awareness. The recent implementation of CMS HAC (Hospital Acquired Condition) penalties is driving increased awareness and momentum as more and more hospitals turn to AEM® Technology as a solution to stray energy incidents."
Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, CO, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2014 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com
www.encision.com
Encision Inc. |
Condensed Balance Sheets |
(Amounts in thousands) |
(Unaudited) |
|
|
| December 31, 2014 |
| March 31, 2014 |
ASSETS |
|
|
|
|
Cash and cash equivalents |
| $ 688 |
| $ 1,690 |
Accounts receivable, net |
| 1,014 |
| 863 |
Inventories, net |
| 2,088 |
| 2,224 |
Prepaid expenses |
| 212 |
| 65 |
Total current assets |
| 4,002 |
| 4,842 |
Equipment, net |
| 853 |
| 1,106 |
Patents, net |
| 257 |
| 249 |
Other assets |
| 18 |
| 14 |
Total assets |
| $ 5,130 |
| $ 6,211 |
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
Accounts payable |
| 581 |
| 666 |
Accrued compensation |
| 305 |
| 265 |
Other accrued liabilities |
| 420 |
| 409 |
Lease and deferred rent payable – short term |
| 30 |
| 97 |
Line of credit |
| 84 |
| -- |
Total current liabilities |
| 1,420 |
| 1,437 |
Lease and deferred rent payable – long term |
| 109 |
| 186 |
Total liabilities |
| 1,529 |
| 1,623 |
Common stock and additional paid-in capital |
| 23,592 |
| 23,545 |
Accumulated (deficit) |
| (19,991) |
| (18,957) |
Total shareholders' equity |
| 3,601 |
| 4,588 |
Total liabilities and shareholders' equity |
| $ 5,130 |
| $ 6,211 |
Encision Inc. |
Condensed Statements of Operations |
(Amounts in thousands, except per share information) |
(Unaudited) |
|
|
| Three Months Ended |
| Nine Months Ended |
|
| December 31, 2014 |
| December 31, 2013 |
| December 31, 2014 |
| December 31, 2013 |
Net revenue |
| 2,608 |
| 2,716 |
| 7,364 |
| 8,043 |
Cost of revenue |
| 1,392 |
| 1,292 |
| 3,851 |
| 3,754 |
Gross profit |
| 1,216 |
| 1,424 |
| 3,513 |
| 4,289 |
Operating expenses: |
|
|
|
|
|
|
|
|
Sales and marketing |
| 791 |
| 601 |
| 2,175 |
| 2,266 |
General and administrative |
| 434 |
| 361 |
| 1,185 |
| 1,069 |
Research and development |
| 354 |
| 364 |
| 1,026 |
| 1,068 |
Total operating expenses |
| 1,579 |
| 1,326 |
| 4,386 |
| 4,403 |
Operating income (loss) |
| (363) |
| 98 |
| (873) |
| (114) |
Interest and other expense, net |
| (54) |
| (65) |
| (161) |
| (215) |
Income (loss) before provision for income taxes |
| (417) |
| 33 |
| (1,034) |
| (329) |
Provision for income taxes |
| –– |
| –– |
| –– |
| –– |
Net income (loss) |
| $(417) |
| $ 33 |
| $ (1,034) |
| $ (329) |
Net income (loss) per share—basic and diluted |
| $(0.04) |
| $ 0.00 |
| $ (0.10) |
| $ (0.04) |
Basic weighted average number of shares |
| 10,673 |
| 8,616 |
| 10,673 |
| 8,346 |
Diluted weighted average number of shares |
| 10,673 |
| 8,620 |
| 10,673 |
| 8,346 |
|
|
|
|
|
|
|
|
|
|
